Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal

Diabetic Medicine

Volumn 24, Issue 12, 2007, Pages 1424-1429

  Nyback Nakell A ^a   Adamson, U ^a   Lins, P E ^a   Landstedt Hallin, L ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

C peptide; Combined therapy; Sulphonylurea withdrawal; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LONG TERM CARE; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SINGLE DRUG DOSE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PILOT PROJECTS; SULFONYLUREA COMPOUNDS;

EID: 36549028270     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02286.x     Document Type: Article

References (26)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999 281 : 2005 2012.
2. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992 15 : 953 959.
3. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996 156 : 259 264.
4. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995 44 : 1249 1258.
5. Landstedt-Hallin L, Arner P, Lins PE, Bolinder J, Olsen H, Groop L. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team. Diabet Med 1999 16 : 827 834.
6. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003 26 : 2231 2237.
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 2443.
8. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995 44 : 165 172.
9. Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995 18 : 307 314.
10. Clauson P, Karlander S, Steen L, Efendic S. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. Diabet Med 1996 13 : 471 477.
11. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995 18 : 1183 1186.
12. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996 19 : 1326 1332.
13. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998 21 : 1052 1057.
14. Olsson PO, Lindstrom T. Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 2002 28 : 272 277.
15. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002 143 : 339 342.
16. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005 90 : 501 506.
17. Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 2005 19 : 60 64.
18. IDF. Global Guidelines for Type 2 Diabetes. Brussels : International Diabetes Federation, 2006.
19. Nobels F, Van Gaal L, Rillaerts E, De Leeuw I. Effect of oral anti-diabetic drug withdrawal in Type 2 diabetes. Diabet Med 1989 6 : 149 151.
20. Lev-Ran A, Yerushalmy Y, Weissglas L, Pertsis V, Ishay JS, Hwang DL. In most poorly controlled glyburide-treated type 2 diabetic patients drug withdrawal causes further increase in glycemia not accompanied by changes in insulin secretion. Horm Metab Res 1998 30 : 108 110.
21. Tong PC, Chow CC, Jorgensen LN, Cockram CS. The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Res Clin Pract 2002 57 : 93 98.
22. Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. Progressive deterioration of beta-cell function in non-obese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab 1996 22 : 185 191.
23. Lebovitz HE, Pasmantier R. Combination insulin-sulfonylurea therapy. Diabetes Care 1990 13 : 667 675.
24. Ravnik-Oblak M, Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Res Clin Pract 1995 30 : 27 35.
25. Trischitta V, Italia S, Raimondo M, Guardabasso V, Licciardello C, Runello F et al. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? J Endocrinol Invest 1998 21 : 744 747.
26. Jonsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001 3 : 403 409.